FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317558497> ?p ?o ?g. }

• W2317558497 endingPage "311" @default.
• W2317558497 startingPage "311.2" @default.
• W2317558497 abstract "<h3>Background</h3> There are no guidelines for the treatment of SAPHO (Synovitis, Acne, Pustulosis, Osteitis, Hyperostosis) syndrome, particularly in the situation of inadequate response to NSAIDs. Bone involvement (hyperostosis, osteitis) may legitimate the therapeutic use of bisphosphonates. <h3>Objectives</h3> The aim of this study was to evaluate efficacy and tolerance of intravenous (IV) pamidronate in patients with SAPHO. <h3>Methods</h3> Open monocentric retrospective study including patients with SAPHO syndrome (Benhamou “criteria”) and treated with IV pamidronate. Main characteristics of the disease and the treatments were recorded. Pamidronate was administered IV, 60 or 120 mg (one or 2 infusions), eventually repeated evey 4 weeks. Efficacy was assessed by global patient VAS, % of improvement, physician9s judgment and biologic parameters (ESR, CRP). Side effects were recorded. <h3>Results</h3> 22 patients were evaluable: 19 women, mean age 48 years, mean disease duration 5.8 years. Skin involvement was present in 18 patients, 22 patients had osteitis, 4 hyperostosis and 13 a sterno clavicular involvement. Initial CRP was 16±22 mg/l, ESR 25 and VAS 67±21 mm. The mean number of infusions was 5.6 (1 to 23). A significant improvement is obvious at month 1 (VAS 44±18; p=0.01), no more significative at month 2 (p=0.06). Physician9s judgment was: efficacy (n=13), partial or transient efficacy (n=8), inefficacy (n=1). In case of efficacy, the mean duration of efficacy under treatment was 7 months. A non significant decrease in ESR was observed at month 1 (25 to 14 mm). Side effects were noted in 11 cases: flu-like syndrome (N=5), fever (3), hypocalcemia, conjunctivitis, headache, vein inflammation. No predictive factor for good response could be found in these patients. <h3>Conclusions</h3> This study suggests a modest global efficacy, variable and transitory, of IV pamidronate treatment in SAPHO syndrome. Analysis of the results remains difficult in the absence of validated response criteria in this heterogeneous disease. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1582" @default.
• W2317558497 created "2016-06-24" @default.
• W2317558497 creator A5022620505 @default.
• W2317558497 creator A5038051042 @default.
• W2317558497 creator A5046645298 @default.
• W2317558497 creator A5064173097 @default.
• W2317558497 date "2014-06-01" @default.
• W2317558497 modified "2023-09-24" @default.
• W2317558497 title "THU0373 Pamidronate Treatment of SAPHO Syndrome: A Retrospective Study of 22 Cases" @default.
• W2317558497 doi "https://doi.org/10.1136/annrheumdis-2014-eular.1582" @default.
• W2317558497 hasPublicationYear "2014" @default.
• W2317558497 type Work @default.
• W2317558497 sameAs 2317558497 @default.
• W2317558497 citedByCount "0" @default.
• W2317558497 crossrefType "journal-article" @default.
• W2317558497 hasAuthorship W2317558497A5022620505 @default.
• W2317558497 hasAuthorship W2317558497A5038051042 @default.
• W2317558497 hasAuthorship W2317558497A5046645298 @default.
• W2317558497 hasAuthorship W2317558497A5064173097 @default.
• W2317558497 hasConcept C126322002 @default.
• W2317558497 hasConcept C141071460 @default.
• W2317558497 hasConcept C167135981 @default.
• W2317558497 hasConcept C2776674182 @default.
• W2317558497 hasConcept C2777077863 @default.
• W2317558497 hasConcept C2779234776 @default.
• W2317558497 hasConcept C2779244835 @default.
• W2317558497 hasConcept C2779782008 @default.
• W2317558497 hasConcept C2780551157 @default.
• W2317558497 hasConcept C2781343496 @default.
• W2317558497 hasConcept C71924100 @default.
• W2317558497 hasConcept C90924648 @default.
• W2317558497 hasConceptScore W2317558497C126322002 @default.
• W2317558497 hasConceptScore W2317558497C141071460 @default.
• W2317558497 hasConceptScore W2317558497C167135981 @default.
• W2317558497 hasConceptScore W2317558497C2776674182 @default.
• W2317558497 hasConceptScore W2317558497C2777077863 @default.
• W2317558497 hasConceptScore W2317558497C2779234776 @default.
• W2317558497 hasConceptScore W2317558497C2779244835 @default.
• W2317558497 hasConceptScore W2317558497C2779782008 @default.
• W2317558497 hasConceptScore W2317558497C2780551157 @default.
• W2317558497 hasConceptScore W2317558497C2781343496 @default.
• W2317558497 hasConceptScore W2317558497C71924100 @default.
• W2317558497 hasConceptScore W2317558497C90924648 @default.
• W2317558497 hasIssue "Suppl 2" @default.
• W2317558497 hasLocation W23175584971 @default.
• W2317558497 hasOpenAccess W2317558497 @default.
• W2317558497 hasPrimaryLocation W23175584971 @default.
• W2317558497 hasRelatedWork W1976472148 @default.
• W2317558497 hasRelatedWork W1995099863 @default.
• W2317558497 hasRelatedWork W2093152953 @default.
• W2317558497 hasRelatedWork W2351501079 @default.
• W2317558497 hasRelatedWork W2366262139 @default.
• W2317558497 hasRelatedWork W2441959390 @default.
• W2317558497 hasRelatedWork W2470285168 @default.
• W2317558497 hasRelatedWork W3204873637 @default.
• W2317558497 hasRelatedWork W3214460186 @default.
• W2317558497 hasRelatedWork W4386191466 @default.
• W2317558497 hasVolume "73" @default.
• W2317558497 isParatext "false" @default.
• W2317558497 isRetracted "false" @default.
• W2317558497 magId "2317558497" @default.
• W2317558497 workType "article" @default.